You are here: Industry Insights > Market News > India to assess side effects of COVID-19 vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Brexpiprazole Intermediate CAS:913613-82-8

Erythorbic Acid (Molecular Formula:C₆H₈O₆)

Sodium Erythorbate(Molecular Formula:C₆H₇NaO₆·H₂O)

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

India to assess side effects of COVID-19 vaccine

expresspharmaApril 12, 2021

Tag: India , COVID-19 vaccine , side effect , blood clot

Favorites

A panel of Indian experts is investigating if there are any domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in the country, reported Mint, a financial newspaper.

India is currently administering AstraZeneca’s COVID-19 vaccine and a shot developed at home by Bharat Biotech.

Several countries in Europe have announced restrictions on the use of the AstraZeneca vaccine in younger people, after a link was found to very rare blood clots, mostly in women under 60 years of age within two weeks of vaccination.

Previous:Remdesivir’s price must not be more than Rs 1400 per vial: Maha Health Minister

Next:Biogen and Bio-Thera enter licencing agreement for arthritis biosimilar

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

India to assess side effects of COVID-19 vaccine | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Top Quality Indian Bread P.E.

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect

Mifepristone (INDIA DMF)

Evening Primrose Oil (OEM/ODM) | Evening Primrose Oil From India / natural Evening Prim rose Oil

100% Pure Freeze Dried Black Berry Anthocyanin Juice Indian Instant Fruit Blackberry Powder

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Factory Free Sample Bulk Food Pure Grade Natural India Herbal Plant Extract Madder Root Extract

Indian Trum etflower Seed Extract

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect by hualan biological

PHENOXYMETHYL PENICILLIN POTASSIUM

India to assess side effects of COVID-19 vaccine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>